Tradewinds Capital Management LLC reduced its stake in Merck & Company, Inc. (NYSE:MRK) by 6.8% during the second quarter, according to its most recent filing with the SEC. The fund owned 3,691 shares of the company’s stock after selling 271 shares during the quarter. Tradewinds Capital Management LLC’s holdings in Merck & were worth $237,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the stock. Boston Partners boosted its holdings in shares of Merck & by 2.6% in the 1st quarter. Boston Partners now owns 19,935,016 shares of the company’s stock worth $1,266,671,000 after buying an additional 500,476 shares during the last quarter. Clearbridge Investments LLC raised its stake in Merck & by 0.6% in the 1st quarter. Clearbridge Investments LLC now owns 13,414,669 shares of the company’s stock valued at $852,368,000 after acquiring an additional 77,344 shares during the period. Sanders Capital LLC raised its stake in Merck & by 4.0% in the 2nd quarter. Sanders Capital LLC now owns 12,052,595 shares of the company’s stock valued at $835,462,000 after acquiring an additional 458,950 shares during the period. PNC Financial Services Group Inc. raised its stake in Merck & by 0.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,821,563 shares of the company’s stock valued at $624,064,000 after acquiring an additional 41,748 shares during the period. Finally, Bank of Montreal Can raised its stake in Merck & by 8.1% in the 2nd quarter. Bank of Montreal Can now owns 9,723,813 shares of the company’s stock valued at $623,199,000 after acquiring an additional 732,720 shares during the period. 72.86% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Merck & Company, Inc. (MRK) Shares Sold by Tradewinds Capital Management LLC” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2982065/merck-company-inc-mrk-shares-sold-by-tradewinds-capital-management-llc.html.
Shares of Merck & Company, Inc. (MRK) opened at 63.11 on Wednesday. The stock has a market cap of $172.12 billion, a price-to-earnings ratio of 34.17 and a beta of 0.80. Merck & Company, Inc. has a 52 week low of $58.29 and a 52 week high of $66.80. The firm has a 50-day moving average price of $64.51 and a 200 day moving average price of $63.71.
Merck & (NYSE:MRK) last announced its earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.14. The firm had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.93 EPS. On average, analysts forecast that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.
A number of brokerages recently issued reports on MRK. Leerink Swann boosted their price objective on Merck & from $69.00 to $70.00 and gave the company a “market perform” rating in a research note on Monday. Jefferies Group LLC restated a “sell” rating and issued a $55.00 price objective on shares of Merck & in a research note on Friday, October 20th. BMO Capital Markets set a $70.00 price objective on Merck & and gave the company a “buy” rating in a research note on Wednesday, October 18th. Citigroup Inc. upgraded Merck & from a “neutral” rating to a “buy” rating and set a $72.00 price objective on the stock in a research note on Wednesday, October 18th. Finally, Zacks Investment Research upgraded Merck & from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $70.67.
Merck & Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.